Blog
RSS FeedPosted by Michael Wonder on 17 Feb 2023
Maker of promising Alzheimer’s drug Leqembi expects full FDA approval this summer, expanded Medicare coverage
17 February 2023 - Eisai anticipates about 100,000 patients diagnosed will be eligible for the drug by year three of its ...
Posted by Michael Wonder on 10 Feb 2023
HHS releases initial guidance for Medicare prescription drug inflation rebate program
9 February 2023 - Under President Biden’s prescription drug law, drug companies will pay rebates to the federal government for ...
Posted by Michael Wonder on 07 Feb 2023
Miracle’ cystic fibrosis drug kept out of reach in developing countries
7 February 2023 - Vertex Pharmaceuticals is not making its drug, Trikafta, available in poorer countries, where thousands of diagnosed patients ...
Posted by Michael Wonder on 05 Feb 2023
Release of the Strengthening Medicare Taskforce Report
3 February 2023 - The Strengthening Medicare Taskforce Report is now available. ...
Posted by Michael Wonder on 05 Feb 2023
Smoothing Medicare Part D out of pocket costs under the Inflation Reduction Act
3 February 2023 - The Inflation Reduction Act of 2022 marks the first major overhaul of the Medicare Part D prescription ...
Posted by Michael Wonder on 03 Feb 2023
Strengthening Medicare for the future
3 February 2023 - The Albanese Government has released the Strengthening Medicare Taskforce report. ...
Posted by Michael Wonder on 02 Feb 2023
‘Enough sickness’ to share GP load among pharmacists, nurses
2 February 2023 - Pharmacy Guild of Australia president Trent Twomey says there is enough “demand and sickness” to allow ...
Posted by Michael Wonder on 31 Jan 2023
Medicare drug price negotiation in the United States: implications and unanswered questions
8 December 2022 - The United States is a relatively free pricing market for pharmaceutical manufacturers to set list prices at ...
Posted by Michael Wonder on 30 Jan 2023
Achieving patient centeredness in Medicare’s new drug price negotiation program
27 January 2023 - The Inflation Reduction Act mandated the creation of a Drug Price Negotiation Program focused on developing a ...
Posted by Michael Wonder on 24 Jan 2023
Reform Medicare to sustain system
25 January 2023 - Australia’s hybrid public/private healthcare system, including the principle of universal coverage through Medicare, has served the nation ...
Posted by Michael Wonder on 16 Jan 2023
Medicare begins to rein in drug costs for older Americans
14 January 2023 - Reforms embedded in the Inflation Reduction Act will bring savings to seniors this year. ...
Posted by Michael Wonder on 13 Jan 2023
As CMS asks for the public’s feedback on implementing the Inflation Reduction Act, unresolved issues related to drug price negotiations remain
11 January 2022 - On 11 January, the Centers for Medicare and Medicaid Services (CMS) announced a timeline for implementation of ...
Posted by Michael Wonder on 21 Nov 2022
Medicare 2.0 - a vision for the future of America’s health insurance plan
21 November 2022 - Medicare is one of the great successes in American social policy. It provides universal health insurance to ...
Posted by Michael Wonder on 21 Nov 2022
Getting the price right: lessons for Medicare price negotiation from peer countries
9 November 2022 - The US pays more for brand-name prescription drugs than any other country and new legislation from August ...
Posted by Michael Wonder on 06 Nov 2022
Independent review into Medicare compliance
5 November 2022 - The Albanese Government has appointed respected health economist Dr Pradeep Philip to conduct an independent review into ...